About Myomo (NYSEAMERICAN:MYO)
Myomo, Inc. is a United States-based medical device company specializing in myoelectric orthotics for people with neurological disorders. The Company's products help to restore function in individuals with neuromuscular conditions, such as brachial plexus injury, spinal cord injury, multiple sclerosis and stroke. Its MyoPro myoelectric limb orthosis is a powered brace that supports a weakened and deformed arm for functional use. The MyoPro is an elbow/wrist/Hand orthosis, which supports the arm and helps to bend and straighten the arm at the elbow. The brace provides assistive function for joint motion that enables a user to self-initiate and control movements of a partially paralyzed arm using their own muscle signals. When the user tries to bend their arm, sensors in the brace detect the weak muscle signal, which activates the motor to amplify their weak muscle signal to help bend and move their arm. The brace uses non-invasive skin sensors.
Industry, Sector and Symbol:
- Industry: Medical Equipment, Supplies & Distribution - NEC
- Sub-Industry: N/A
- Sector: N/A
- Symbol: NYSEAMERICAN:MYO
- CUSIP: N/A
- Web: myomo.com
- Outstanding Shares: 6,110,000
Frequently Asked Questions for Myomo (NYSEAMERICAN:MYO)
What is Myomo's stock symbol?
Myomo trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MYO."
Are investors shorting Myomo?
Myomo saw a increase in short interest in October. As of October 31st, there was short interest totalling 209,617 shares, an increase of 208.1% from the October 13th total of 68,045 shares. Based on an average daily trading volume, of 74,202 shares, the days-to-cover ratio is currently 2.8 days. Approximately 4.7% of the shares of the stock are short sold.
Who are some of Myomo's key competitors?
Some companies that are related to Myomo include Actinium Pharmaceuticals (ATNM), WidePoint (WYY), Wireless Telecom Group (WTT), IEC Electronics Corp (IEC), Nevada Gold & Casinos (UWN), Electromed (ELMD), Golden Minerals Co (AUMN), General Moly (GMO), TransAtlantic Petroleum Ltd (TAT), CorMedix (CRMD), Intellicheck (IDN), Enservco Corp (ENSV), Reed's (REED), Paramount Gold Nevada Corp (PZG), Superior Drilling Products (SDPI), Can Fite Biopharma Ltd (CANF), EnSync (ESNC) and Houston American Energy (HUSA).
Who are Myomo's key executives?
Myomo's management team includes the folowing people:
- Steve Kelly, Founder, Chairman of the Board, President and Chief Operating Officer
- Paul R. Gudonis, Chief Executive Officer, Director
- Ralph A. Goldwasser CPA, Chief Financial Officer
- Jonathan Naft, General Manager - O&P
- Fredrick Nahm M.D. Ph.D., Medical Director
How do I buy Myomo stock?
Shares of Myomo can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Myomo's stock price today?
One share of Myomo stock can currently be purchased for approximately $4.70.
How big of a company is Myomo?
Myomo has a market capitalization of $28.11 million.
How can I contact Myomo?
Myomo's mailing address is One Broadway, 14Th Floor, CAMBRIDGE, MA 02142, United States. The company can be reached via phone at +1-617-9969058.
MarketBeat Community Rating for Myomo (NYSEAMERICAN MYO)MarketBeat's community ratings are surveys of what our community members think about Myomo and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Myomo (NYSEAMERICAN:MYO) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Myomo (NYSEAMERICAN:MYO)
Analysts' Ratings History for Myomo (NYSEAMERICAN:MYO)
(Data available from 11/19/2015 forward)
|10/2/2017||HC Wainwright||Reiterated Rating||Buy|
Earnings History for Myomo (NYSEAMERICAN:MYO)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Myomo (NYSEAMERICAN:MYO)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Myomo (NYSEAMERICAN:MYO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Myomo (NYSEAMERICAN MYO)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for Myomo (NYSEAMERICAN MYO)
Financials are not available for this stock.
Myomo (NYSEAMERICAN MYO) Chart for Sunday, November, 19, 2017